Comparing of Pluristem Therapeutics Inc. (PSTI) and Incyte Corporation (NASDAQ:INCY)

Pluristem Therapeutics Inc. (NASDAQ:PSTI) and Incyte Corporation (NASDAQ:INCY), are influenced by contrast since they are both players in the Biotechnology. These factors are particularly influence the analyst recommendations, profitability, risk, institutional ownership, dividends, earnings and valuation of the two firms.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Pluristem Therapeutics Inc. N/A 1370.69 27.98M -0.25 0.00
Incyte Corporation 1.88B 9.26 109.49M 0.50 169.46

Table 1 highlights Pluristem Therapeutics Inc. and Incyte Corporation’s top-line revenue, earnings per share and valuation.

Profitability

Table 2 provides us Pluristem Therapeutics Inc. and Incyte Corporation’s net margins, return on assets and return on equity.

Net Margins Return on Equity Return on Assets
Pluristem Therapeutics Inc. 0.00% -113.7% -81.6%
Incyte Corporation 5.82% 6.2% 4.4%

Volatility and Risk

Pluristem Therapeutics Inc.’s volatility measures that it’s 34.00% more volatile than Standard & Poor’s 500 due to its 1.34 beta. Incyte Corporation’s 1.39 beta is the reason why it is 39.00% more volatile than Standard & Poor’s 500.

Liquidity

Pluristem Therapeutics Inc. has a Current Ratio of 2.5 and a Quick Ratio of 2.5. Competitively, Incyte Corporation’s Current Ratio is 4.3 and has 4.3 Quick Ratio. Incyte Corporation’s better ability to pay short and long-term obligations than Pluristem Therapeutics Inc.

Analyst Ratings

The next table highlights the given recommendations and ratings for Pluristem Therapeutics Inc. and Incyte Corporation.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Pluristem Therapeutics Inc. 0 0 0 0.00
Incyte Corporation 0 4 5 2.56

Meanwhile, Incyte Corporation’s average target price is $86.8, while its potential upside is 6.78%.

Institutional and Insider Ownership

The shares of both Pluristem Therapeutics Inc. and Incyte Corporation are owned by institutional investors at 5.4% and 94% respectively. 10.7% are Pluristem Therapeutics Inc.’s share held by insiders. Insiders Competitively, held 0.3% of Incyte Corporation shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Pluristem Therapeutics Inc. -6.85% -16.57% -11.17% -28.4% -32.67% 21.74%
Incyte Corporation -1.69% 5.98% 29.88% 15.29% 2.79% 34.31%

For the past year Pluristem Therapeutics Inc. was less bullish than Incyte Corporation.

Summary

On 10 of the 11 factors Incyte Corporation beats Pluristem Therapeutics Inc.

Pluristem Therapeutics Inc., together with its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company in Israel. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders. The company develops PLacental eXpanded (PLX) cell therapy products, including PLX-PAD cells, which is Phase III clinical trial for the treatment of critical limb ischemia (CLI) in patients ineligible for revascularization, recovery after surgery for femoral neck fracture, and acute radiation syndrome (ARS), as well as peripheral and cardiovascular, and orthopedic diseases. It also develops PLX-R18 cells that is in Phase I clinical trial for incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as conducts various in-vivo studies for the evaluation of PLX-R18 for the treatment of ARS. The company has collaborative research agreement with the Berlin-Brandenburg Center for Regenerative Therapies; and a license and commercialization agreement for conducting clinical trials and commercialization of its PLX-PAD product in South Korea related to the treatment CLI and intermediate claudication. Pluristem Therapeutics Inc. was founded in 2001 and is based in Haifa, Israel.

Incyte Corporation focuses on the discovery, development, and commercialization of proprietary therapeutics in oncology in the United States and internationally. It offers JAKAFI for the treatment of myelofibrosis and polycythemia vera cancers. The companyÂ’s clinical stage products include ruxolitinib cream that is in Phase II clinical trial for the treatment of alopecia areata and atopic dermatitis; and baricitinib, which is in Phase III clinical trial for treatment of rheumatoid arthritis. In addition, it is developing itacitinib that is in Phase I/II clinical trials in combination with osimertinib for non-small cell lung cancer (NSCLC); INCB52793, INCB54329 (BRD), INCB57643 (BRD), and INCB53914 (PIM), which are in Phase I/II trials for the treatment of advanced malignancies; INCB54828 (FGFR1/2/3) that is in Phase II clinical trial the treatment of bladder cancer, cholangiocarcinoma, and 8p11 MPNs; INCB59872 (LSD1), which is in Phase II clinical trial the treatment of acute myeloid leukemia and small cell lung cancer; and capmatinib that is in Phase II clinical trial for the treatment of NSCLC and liver cancer. Further, the companyÂ’s clinical stage products include epacadostat, which is in Phase II clinical trial for the treatment of various tumors, and in Phase I/II clinical trials for the treatment of NSCLC and bladder cancer, as well as in Phase III clinical trial for the treatment of advanced melanoma; and INCB01158, INCSHR1210, INCAGN1876 (GITR), and INCAGN1949 (OX40), which are in Phase I/II clinical trials for the treatment of solid tumors. It markets its JAKAFI product through a network of specialty pharmacy providers and wholesalers. The company has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Jiangsu Hengrui Medicine Co., Ltd.; Merus N.V.; Calithera Biosciences, Inc; Pfizer Inc; and Abramson Cancer Center. Incyte Corporation was founded in 1991 and is headquartered in Wilmington, Delaware.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.